Difference between revisions of "Tagraxofusp (Elzonris)"
Jump to navigation
Jump to search
m |
m |
||
| (12 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
| − | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/dt388il3-fusion-protein-sl-401 NCI Drug Dictionary]: A recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with potential antineoplastic activity. Upon intravenous administration, the IL3 moiety of the tagraxofusp-erzs binds to IL3 receptors on cells expressing the receptor. Subsequently, the DT(388) toxin moiety, which contains both translocation and catalytic domains, is transported across the cell membrane via endocytosis. Within the cytosol, the catalytic domain of the toxin both catalyzes the ADP-ribosylation of, and inactivates, translation elongation factor 2 (EF-2), which results in the inhibition of translation during protein synthesis. | |
| − | = | + | ==Diseases for which it is established== |
| − | + | *[[Blastic plasmacytoid dendritic cell neoplasm]] | |
| − | [[ | + | ==History of changes in FDA indication== |
| − | + | *2018-12-21: Initial approval for [[Blastic plasmacytoid dendritic cell neoplasm|blastic plasmacytoid dendritic cell neoplasm (BPDCN)]] in adults and in pediatric patients 2 years and older. ''(Based on STML-401-0114)'' | |
| − | + | ==History of changes in EMA indication== | |
| + | *2021-01-07: Initial authorization as Elzonris | ||
| + | ==Also known as== | ||
| + | *'''Code name:''' SL-401 | ||
| + | *'''Generic name:''' tagraxofusp-erzs | ||
| + | *'''Brand name:''' Elzonris | ||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:IL-3 fused immunotoxins]] | ||
[[Category:Blastic plasmacytoid dendritic cell neoplasm medications]] | [[Category:Blastic plasmacytoid dendritic cell neoplasm medications]] | ||
| + | |||
| + | [[Category:FDA approved in 2018]] | ||
| + | [[Category:EMA approved in 2021]] | ||
Latest revision as of 12:25, 4 July 2023
Mechanism of action
From the NCI Drug Dictionary: A recombinant protein consisting of human interleukin 3 (IL3) fused to the first 388 amino acids of diphtheria toxin [DT(388)] (DT388IL3) with potential antineoplastic activity. Upon intravenous administration, the IL3 moiety of the tagraxofusp-erzs binds to IL3 receptors on cells expressing the receptor. Subsequently, the DT(388) toxin moiety, which contains both translocation and catalytic domains, is transported across the cell membrane via endocytosis. Within the cytosol, the catalytic domain of the toxin both catalyzes the ADP-ribosylation of, and inactivates, translation elongation factor 2 (EF-2), which results in the inhibition of translation during protein synthesis.
Diseases for which it is established
History of changes in FDA indication
- 2018-12-21: Initial approval for blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older. (Based on STML-401-0114)
History of changes in EMA indication
- 2021-01-07: Initial authorization as Elzonris
Also known as
- Code name: SL-401
- Generic name: tagraxofusp-erzs
- Brand name: Elzonris